[go: up one dir, main page]

WO1999039740A8 - Sensitizing cells to compounds using lipid-mediated gene and compound delivery - Google Patents

Sensitizing cells to compounds using lipid-mediated gene and compound delivery

Info

Publication number
WO1999039740A8
WO1999039740A8 PCT/CA1999/000089 CA9900089W WO9939740A8 WO 1999039740 A8 WO1999039740 A8 WO 1999039740A8 CA 9900089 W CA9900089 W CA 9900089W WO 9939740 A8 WO9939740 A8 WO 9939740A8
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
compounds
mediated gene
compound delivery
sensitizing cells
Prior art date
Application number
PCT/CA1999/000089
Other languages
French (fr)
Other versions
WO1999039740A2 (en
WO1999039740A3 (en
WO1999039740A9 (en
Inventor
Ian Maclachlan
Roger W Graham
Susan S Buchkowsky
Original Assignee
Inex Pharmaceuticals Corp
Ian Maclachlan
Roger W Graham
Susan S Buchkowsky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27535971&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999039740(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inex Pharmaceuticals Corp, Ian Maclachlan, Roger W Graham, Susan S Buchkowsky filed Critical Inex Pharmaceuticals Corp
Priority to CA002319468A priority Critical patent/CA2319468A1/en
Priority to EP99903556A priority patent/EP1053022A2/en
Priority to AU24056/99A priority patent/AU754611B2/en
Priority to JP2000530237A priority patent/JP2002528381A/en
Publication of WO1999039740A2 publication Critical patent/WO1999039740A2/en
Publication of WO1999039740A8 publication Critical patent/WO1999039740A8/en
Publication of WO1999039740A3 publication Critical patent/WO1999039740A3/en
Publication of WO1999039740A9 publication Critical patent/WO1999039740A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to methods and compositions for sensitizing a cell to a compound such as a prodrug.
PCT/CA1999/000089 1998-02-03 1999-02-03 Sensitizing cells to compounds using lipid-mediated gene and compound delivery WO1999039740A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002319468A CA2319468A1 (en) 1998-02-03 1999-02-03 Sensitizing cells to compounds using lipid-mediated gene and compound delivery
EP99903556A EP1053022A2 (en) 1998-02-03 1999-02-03 Sensitizing cells to compounds using lipid-mediated gene and compound delivery
AU24056/99A AU754611B2 (en) 1998-02-03 1999-02-03 Sensitizing cells to compounds using lipid-mediated gene and compound delivery
JP2000530237A JP2002528381A (en) 1998-02-03 1999-02-03 Sensitization of cells to compounds utilizing lipid-mediated gene and compound transfer

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US7359898P 1998-02-03 1998-02-03
US8691798P 1998-05-27 1998-05-27
US10142998P 1998-09-22 1998-09-22
US11238498P 1998-12-14 1998-12-14
US24310299A 1999-02-02 1999-02-02
US60/073,598 1999-02-02
US09/243,102 1999-02-02
US60/101,429 1999-02-02
US60/086,917 1999-02-02
US60/112,384 1999-02-02

Publications (4)

Publication Number Publication Date
WO1999039740A2 WO1999039740A2 (en) 1999-08-12
WO1999039740A8 true WO1999039740A8 (en) 1999-09-23
WO1999039740A3 WO1999039740A3 (en) 1999-10-28
WO1999039740A9 WO1999039740A9 (en) 1999-11-25

Family

ID=27535971

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CA1999/000089 WO1999039740A2 (en) 1998-02-03 1999-02-03 Sensitizing cells to compounds using lipid-mediated gene and compound delivery
PCT/CA1999/000090 WO1999039741A2 (en) 1998-02-03 1999-02-03 Systemic delivery of serum stable plasmid lipid particles for cancer therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000090 WO1999039741A2 (en) 1998-02-03 1999-02-03 Systemic delivery of serum stable plasmid lipid particles for cancer therapy

Country Status (7)

Country Link
EP (1) EP1053023B2 (en)
JP (1) JP2002502831A (en)
AT (1) ATE366121T1 (en)
AU (1) AU749881B2 (en)
CA (2) CA2319468A1 (en)
DE (1) DE69936444T3 (en)
WO (2) WO1999039740A2 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835393B2 (en) 1998-01-05 2004-12-28 University Of Washington Enhanced transport using membrane disruptive agents
EP1459761A4 (en) * 2001-06-08 2005-04-13 Fourth Military Medical Univ PHARMACEUTICAL KIT COMPRISING A HUMAN CARBOXYPEPTIDASE FUSION PROTEIN DIRECTED AGAINST SINGLE PLINMATIC PROTEIN SEMINAL PROTEIN ANTIBODY AND PROMEDICAMENT
JP2005517394A (en) 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド Composition for virus preservation
CN100543036C (en) 2002-05-06 2009-09-23 得克萨斯州大学系统董事会 Targeting proteins for delivery of therapeutic or diagnostic reagents
EP3238738B1 (en) 2008-11-10 2020-09-23 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
WO2018081480A1 (en) 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
EP3596112A2 (en) 2017-03-17 2020-01-22 Newcastle University Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
WO2018191719A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipid delivery of therapeutic agents to adipose tissue
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
EP3852911B1 (en) 2018-09-21 2025-01-22 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
PE20220968A1 (en) 2019-08-14 2022-06-10 Acuitas Therapeutics Inc ENHANCED LIPID NANOPARTICLES FOR THE DELIVERY OF NUCLEIC ACIDS
IL296781A (en) 2020-03-30 2022-11-01 BioNTech SE RNA compositions targeting claudin-18.2
AU2021293197A1 (en) 2020-06-15 2023-02-09 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery for muscular dystrophies
EP4319803A1 (en) 2021-04-08 2024-02-14 Vaxthera SAS Coronavirus vaccine comprising a mosaic protein
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
CN118317944A (en) 2021-09-14 2024-07-09 雷纳嘉德医疗管理公司 Acyclic lipids and methods of use thereof
JP2024533865A (en) 2021-09-14 2024-09-12 レナゲード セラピューティクス マネージメント インコーポレイテッド Cyclic lipids and methods of use thereof
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
CN118829625A (en) 2021-11-16 2024-10-22 赛欧生物医药股份有限公司 Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2023091787A1 (en) 2021-11-22 2023-05-25 Senda Biosciences, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023147090A1 (en) 2022-01-27 2023-08-03 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
US20250205167A1 (en) 2022-03-25 2025-06-26 Sail Biomedicines, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
AU2023251104A1 (en) 2022-04-07 2024-10-17 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
JP2025516674A (en) 2022-05-13 2025-05-30 ビオンテック エスエー RNA compositions targeting HIV
KR20250021330A (en) 2022-05-25 2025-02-12 비온테크 에스이 RNA compositions for delivering monkeypox antigens and related methods
JP2025518221A (en) 2022-05-30 2025-06-12 ビオンテック・ソシエタス・エウロパエア Complexes for delivery of nucleic acids
AU2023334610A1 (en) 2022-08-31 2025-03-13 Sail Biomedicines, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2024064934A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of plasmodium csp antigens and related methods
WO2024063789A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024064931A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of liver stage antigens and related methods
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
AU2023357320A1 (en) 2022-10-06 2025-04-17 BioNTech SE Rna compositions targeting claudin-18.2
WO2024141955A1 (en) 2022-12-28 2024-07-04 BioNTech SE Rna compositions targeting hiv
WO2024229309A2 (en) 2023-05-03 2024-11-07 Manifold Biotechnologies, Inc. Methodsand compositions for high-throughput protein delivery, screening, and detection
WO2024228044A1 (en) 2023-05-03 2024-11-07 BioNTech SE Optimized csp variants and related methods
WO2024228150A1 (en) 2023-05-03 2024-11-07 BioNTech SE Optimized csp variants and related methods
WO2025024324A1 (en) 2023-07-21 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025024335A2 (en) 2023-07-21 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025024337A1 (en) 2023-07-24 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025027089A1 (en) 2023-08-01 2025-02-06 BioNTech SE Ionizable thiolipids and uses thereof
WO2025026545A1 (en) 2023-08-01 2025-02-06 BioNTech SE Ionizable thioplipids and uses thereof
WO2025027579A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
WO2025027576A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
WO2025030097A2 (en) 2023-08-03 2025-02-06 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2025030154A1 (en) 2023-08-03 2025-02-06 The Trustees Of The University Of Pennsylvania Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
WO2025054556A1 (en) 2023-09-07 2025-03-13 BioNTech SE Rna compositions for delivery of mpox antigens and related methods
WO2025057088A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
WO2025056938A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
GB202416789D0 (en) 2023-11-15 2025-01-01 BioNTech SE SARS-COV-2 immunogenic compositions
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
WO2025124711A1 (en) 2023-12-13 2025-06-19 BioNTech SE Glycolipid compositions
WO2025134062A2 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025134066A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025133105A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Compositions and methods
WO2025149492A1 (en) 2024-01-08 2025-07-17 BioNTech SE Rna encoding an immune inhibitory il-1 family member
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025184508A1 (en) 2024-03-01 2025-09-04 Acuitas Therapeutics, Inc. Materials and methods for encapsulating therapeutics in lipid nanoparticles
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
AU625013B2 (en) * 1989-11-03 1992-06-25 Vanderbilt University Method of in vivo delivery of functioning foreign genes
WO1993012240A1 (en) 1991-12-17 1993-06-24 The Regents Of The University Of California Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
AU705889B2 (en) * 1993-08-26 1999-06-03 Regents Of The University Of California, The Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides
DE69535405T2 (en) 1994-04-26 2007-11-15 Children's Medical Center Corp., Boston ANGIOSTATIN AND METHOD FOR ITS USE TO AVOID THE ANGIOGENESIS
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9501052D0 (en) 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
AU723163B2 (en) * 1995-06-07 2000-08-17 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US7517858B1 (en) * 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
GB9517001D0 (en) 1995-08-18 1995-10-18 Denny William Enediyne compounds
AU717277B2 (en) 1995-10-23 2000-03-23 Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
GB9523703D0 (en) 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy
US6347397B1 (en) 1999-03-29 2002-02-12 International Business Machines Corporation System, method, and program for providing an object-oriented install architecture
US8266598B2 (en) 2008-05-05 2012-09-11 Microsoft Corporation Bounding resource consumption using abstract interpretation

Also Published As

Publication number Publication date
EP1053023B1 (en) 2007-07-04
WO1999039741A3 (en) 1999-09-30
WO1999039740A2 (en) 1999-08-12
EP1053023A2 (en) 2000-11-22
AU749881B2 (en) 2002-07-04
WO1999039741A2 (en) 1999-08-12
WO1999039740A3 (en) 1999-10-28
DE69936444T2 (en) 2008-03-20
DE69936444T3 (en) 2012-05-10
AU2405799A (en) 1999-08-23
CA2321837C (en) 2011-08-16
CA2319468A1 (en) 1999-08-12
EP1053023B2 (en) 2011-03-30
CA2321837A1 (en) 1999-08-12
ATE366121T1 (en) 2007-07-15
WO1999039740A9 (en) 1999-11-25
DE69936444D1 (en) 2007-08-16
JP2002502831A (en) 2002-01-29

Similar Documents

Publication Publication Date Title
WO1999039740A3 (en) Sensitizing cells to compounds using lipid-mediated gene and compound delivery
AU5420699A (en) Compositions suitable for electrochemical cells
AU3826999A (en) Compositions suitable for electrochemical cells
BG106440A (en) Nitrogen-heterocyclic derivatives as nos inhibitors
AU2002360320A1 (en) Active material for fuel cell anodes incorporating an additive for precharging/activation thereof
AU2003243212A1 (en) Improved fuel cell
AU2001260606A1 (en) Constituent part for fuel cell
MY142109A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
AU6864600A (en) Fuel cell
AU751122C (en) Fuel compositions containing propoxilate
AUPP818099A0 (en) New n-containing heterocyclic compounds
AU2002334658A1 (en) Fuel additives for fuel cell
WO1999059572A8 (en) Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
AU2003235340A1 (en) Separator for fuel cell
AU2002335219A1 (en) Coating material for fuel cell separator
AU2251901A (en) Methods and compounds for inhibiting MRP1
AU2003302735A1 (en) Various filter elements for hydrogen fuel cell
AU1788500A (en) Fuel composition
AU752953C (en) Adding pharmaceutically active compounds to substrates
AU2001261732A1 (en) Composition for delivery of compounds to cells
AU5064900A (en) Herbicidal compositions for paddy fields
AU4800800A (en) Fuel compositions
AU5922199A (en) Transient fuel compensation
AU8631698A (en) A process for the preparation of tetraazamacrocycles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 32/99 UNDER (30) REPLACE "09/243104" BY "09/243102"

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/19-19/19, DRAWINGS, REPLACED BY NEW PAGES 1/18-18/18; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2319468

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2319468

WWE Wipo information: entry into national phase

Ref document number: 1999903556

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 24056/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999903556

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 24056/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999903556

Country of ref document: EP